GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus rating of "Hold" from thirteen research firms. The average target price is $5.52, with one sell rating, six hold ratings, and six buy ratings. Recent analyst actions include Raymond James downgrading from "strong-buy" to "outperform" and Mizuho lowering the price target from $5.00 to $4.00. GoodRx's stock opened at $3.03, with a market cap of $1.05 billion. The company reported $0.08 EPS for the last quarter, missing estimates by $0.01, with revenue of $196.03 million, up 0.4% year-over-year.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been assigned a consensus rating of "Hold" from the thirteen research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $5.5227.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

A number of analysts have weighed in on the company. Raymond James Financial lowered GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Mizuho reduced their price target on GoodRx from $5.00 to $4.00 and set a "neutral" rating for the company in a research report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $6.00 price objective on shares of GoodRx in a research note on Monday, August 11th. Weiss Ratings lowered GoodRx from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Saturday, October 25th. Finally, JPMorgan Chase & Co. reduced their target price on shares of GoodRx from $6.00 to $5.00 and set an "overweight" rating for the company in a report on Tuesday.

Read Our Latest Stock Report on GDRX

Insider Activity

This healthcare stock making a buzz with 160% growth

In related news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business's stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.17% of the stock is currently owned by insiders.

Hedge Funds Weigh In On GoodRx

Several institutional investors and hedge funds have recently bought and sold shares of GDRX. Vanguard Group Inc. increased its position in shares of GoodRx by 7.3% during the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock worth $38,947,000 after purchasing an additional 624,182 shares in the last quarter. Ameriprise Financial Inc. grew its stake in GoodRx by 4.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company's stock worth $24,001,000 after buying an additional 184,734 shares during the last quarter. Petrus Trust Company LTA grew its stake in GoodRx by 7.4% during the 1st quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company's stock worth $13,967,000 after buying an additional 216,926 shares during the last quarter. LSV Asset Management increased its position in GoodRx by 517.1% during the 3rd quarter. LSV Asset Management now owns 2,354,581 shares of the company's stock valued at $9,960,000 after buying an additional 1,973,017 shares in the last quarter. Finally, 8 Knots Management LLC purchased a new stake in GoodRx in the first quarter valued at about $8,106,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Stock Down 1.0%

Gene therapy: Why does it cost millions for a single treatment?

Shares of GoodRx stock opened at $3.03 on Wednesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 3.11 and a quick ratio of 3.11. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 1.57 and a beta of 1.19. The firm's 50-day moving average is $3.97 and its two-hundred day moving average is $4.25. GoodRx has a 1 year low of $2.95 and a 1 year high of $5.81.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. During the same quarter in the prior year, the firm posted $0.08 EPS. The company's revenue for the quarter was up .4% compared to the same quarter last year. GoodRx has set its FY 2025 guidance at EPS. As a group, research analysts expect that GoodRx will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

(Get Free Report)

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Should You Invest $1,000 in GoodRx Right Now?

Before you consider GoodRx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.

While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here